COSMOS Pharma Q3 Analysis: Revenue Growth Outpaces Profit Expansion Amid Margin Pressure
COSMOS Pharmaceutical Corporation (株式会社コスモス薬品), a regional drugstore operator with a strong presence in Kyushu, reported a 7.7% year-over-year (YoY) increase in revenue for the third quarter of its fiscal year 2026 (ending May 2026), driven by its suburban large-format store model and low-price strategy. However, operating profit grew only 1.2% YoY, highlighting margin compression amid rising costs and intensified price competition.
Key Numbers
| Metric | Q3 2026 (JPY bn) | YoY Change |
|---|---|---|
| Revenue | 810.4 | +7.7% |
| Operating Profit | 32.0 | +1.2% |
| Ordinary Income | 33.9 | +0.3% |
| Net Profit | 22.7 | +1.8% |
| Operating Margin | 4.0% | — |
| Equity Ratio | 50.2% | +0.1 ppts |
Business Overview COSMOS Pharmaceutical Corporation operates a chain of drugstores primarily in Kyushu, Japan, with a focus on suburban large-format stores and cost-effective pricing strategies. The company is positioned as a regional player in the highly competitive retail pharmacy sector.
Analysis The 7.7% YoY revenue growth outpaced the industry’s average pace, reflecting the effectiveness of the company’s expansion strategy and low-price initiatives. However, the operating margin of 4.0% remains below the industry average of 6.0%, indicating ongoing pressure from rising costs and competitive pricing. This margin gap suggests that while the company is capturing market share, it is not yet achieving the level of profitability seen by its peers.
Operating profit increased by 1.2% YoY, but this growth is modest compared to the 7.7% revenue increase. This disparity is likely due to rising input costs and increased investment in promotional activities. Ordinary income grew by 0.3% YoY, a minimal increase that may be influenced by non-operating expenses or changes in financial structure.
Net profit rose by 1.8% YoY, reflecting the modest improvements in operating and ordinary income. The equity ratio of 50.2% shows a slight improvement from the previous year, indicating a stable financial structure with a balanced reliance on debt and equity financing.
Next Year Guidance The company has provided preliminary guidance for the full fiscal year 2026 (ending May 2026), with the following projections:
| Metric | FY2026 Guidance (JPY bn) | YoY Change (vs. FY2025) |
|---|---|---|
| Revenue | 1,057.0 | +4.5% |
| Operating Profit | 40.5 | +0.2% |
| Ordinary Income | 43.2 | +0.1% |
| Net Profit | 31.0 | +0.1% |